2Vassallo RR Jr.New paradigms in the management of alloimmune refractoriness to platelet transfusions.Curr Opin Hematol,2007,14:655-663.
3Pomper GJ,Chai L,Snyder EL.Platelet transfusion and alternatives.In Simon TL,Dzik WH,Snyder EL,et al.Rossi's principles of transfusion medicine.3th.Philadelphia:Lippincott William & Wilkins,2002,232-249.
4Demetri GD and Anderson K.Disorders of blood cell production in clinical oncology.In:Abeloft MD,Armitage JO,Lichter AS,et al.Clinical oncology.2nd.北京:科学出版社,2001,628-656.
5Avvisati G,Tirindelli MC,Annibali O.Thrombocytopenia and hemorrhagic risk in cancer patients.Crit Rev Oncol Hematol,2003,48:13-16.
6REBULLA P.Ref ractoriness to platelet t ransfusion[J].Curr Opin Hematol,2002,9:516-520.
7NOVOTN Y VM.Prevention and management of platelet transfusion refractoriness[J].Vox Sang,1999,76:1-13.
